Literature DB >> 29769270

Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses.

Emilie Seydoux1, Hong Liang1, Natasha Dubois Cauwelaert1, Michelle Archer1, Nicholas D Rintala1, Ryan Kramer1, Darrick Carter1,2, Christopher B Fox1,2, Mark T Orr3,2.   

Abstract

The involvement of innate receptors that recognize pathogen- and danger-associated molecular patterns is critical to programming an effective adaptive immune response to vaccination. The synthetic TLR4 agonist glucopyranosyl lipid adjuvant (GLA) synergizes with the squalene oil-in-water emulsion (SE) formulation to induce strong adaptive responses. Although TLR4 signaling through MyD88 and TIR domain-containing adapter inducing IFN-β are essential for GLA-SE activity, the mechanisms underlying the synergistic activity of GLA and SE are not fully understood. In this article, we demonstrate that the inflammasome activation and the subsequent release of IL-1β are central effectors of the action of GLA-SE, as infiltration of innate cells into the draining lymph nodes and production of IFN-γ are reduced in ASC-/- animals. Importantly, the early proliferation of Ag-specific CD4+ T cells was completely ablated after immunization in ASC-/- animals. Moreover, numbers of Ag-specific CD4+ T and B cells as well as production of IFN-γ, TNF-α, and IL-2 and Ab titers were considerably reduced in ASC-/-, NLRP3-/-, and IL-1R-/- mice compared with wild-type mice and were completely ablated in TLR4-/- animals. Also, extracellular ATP, a known trigger of the inflammasome, augments Ag-specific CD4+ T cell responses, as hydrolyzing it with apyrase diminished adaptive responses induced by GLA-SE. These data thus demonstrate that GLA-SE adjuvanticity acts through TLR4 signaling and NLRP3 inflammasome activation to promote robust Th1 and B cell responses to vaccine Ags. The findings suggest that engagement of both TLR and inflammasome activators may be a general paradigm for induction of robust CD4 T cell immunity with combination adjuvants such as GLA-SE.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29769270      PMCID: PMC6008227          DOI: 10.4049/jimmunol.1701604

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  72 in total

1.  Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression.

Authors:  Antonia Fettelschoss; Magdalena Kistowska; Salomé LeibundGut-Landmann; Hans-Dietmar Beer; Pål Johansen; Gabriela Senti; Emmanuel Contassot; Martin F Bachmann; Lars E French; Annette Oxenius; Thomas M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

2.  ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors.

Authors:  Yu Chen; Ross Corriden; Yoshiaki Inoue; Linda Yip; Naoyuki Hashiguchi; Annelies Zinkernagel; Victor Nizet; Paul A Insel; Wolfgang G Junger
Journal:  Science       Date:  2006-12-15       Impact factor: 47.728

Review 3.  The mechanism of action of MF59 - an innately attractive adjuvant formulation.

Authors:  D T O'Hagan; G S Ott; E De Gregorio; A Seubert
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

4.  IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation.

Authors:  Shlomo Z Ben-Sasson; Jane Hu-Li; Juan Quiel; Stephane Cauchetaux; Maya Ratner; Ilana Shapira; Charles A Dinarello; William E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

5.  Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.

Authors:  Mark T Orr; Christopher B Fox; Susan L Baldwin; Sandra J Sivananthan; Elyse Lucas; Susan Lin; Tony Phan; James J Moon; Thomas S Vedvick; Steven G Reed; Rhea N Coler
Journal:  J Control Release       Date:  2013-08-09       Impact factor: 9.776

6.  Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88.

Authors:  Anja Seubert; Samuele Calabro; Laura Santini; Barbara Galli; Alessia Genovese; Sara Valentini; Susanna Aprea; Annalisa Colaprico; Ugo D'Oro; Marzia M Giuliani; Michele Pallaoro; Mariagrazia Pizza; Derek T O'Hagan; Andreas Wack; Rino Rappuoli; Ennio De Gregorio
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

7.  Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.

Authors:  Rhea N Coler; Sylvie Bertholet; Magdalini Moutaftsi; Jeff A Guderian; Hillarie Plessner Windish; Susan L Baldwin; Elsa M Laughlin; Malcolm S Duthie; Christopher B Fox; Darrick Carter; Martin Friede; Thomas S Vedvick; Steven G Reed
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240

8.  Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.

Authors:  Christopher B Fox; Mark T Orr; Neal Van Hoeven; Sarah C Parker; Traci J T Mikasa; Tony Phan; Elyse A Beebe; Ghislain I Nana; Sharvari W Joshi; Mark A Tomai; James Elvecrog; Timothy R Fouts; Steven G Reed
Journal:  J Control Release       Date:  2016-11-12       Impact factor: 9.776

9.  Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity.

Authors:  Amy S McKee; Michael W Munks; Megan K L MacLeod; Courtney J Fleenor; Nico Van Rooijen; John W Kappler; Philippa Marrack
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

10.  ATP release and purinergic signaling in NLRP3 inflammasome activation.

Authors:  Aurélie Gombault; Ludivine Baron; Isabelle Couillin
Journal:  Front Immunol       Date:  2013-01-08       Impact factor: 7.561

View more
  14 in total

Review 1.  Inflammasomes and adaptive immune responses.

Authors:  Katherine A Deets; Russell E Vance
Journal:  Nat Immunol       Date:  2021-02-18       Impact factor: 25.606

Review 2.  Inflammasomes: Their Role in Normal and Complicated Pregnancies.

Authors:  Nardhy Gomez-Lopez; Kenichiro Motomura; Derek Miller; Valeria Garcia-Flores; Jose Galaz; Roberto Romero
Journal:  J Immunol       Date:  2019-12-01       Impact factor: 5.422

Review 3.  NLRP3 inflammasome activation and cell death.

Authors:  Yi Huang; Wen Xu; Rongbin Zhou
Journal:  Cell Mol Immunol       Date:  2021-07-28       Impact factor: 22.096

4.  3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates.

Authors:  Sudhir Pai Kasturi; Mohammed Ata Ur Rasheed; Colin Havenar-Daughton; Mathew Pham; Traci Legere; Zarpheen Jinnah Sher; Yevgeny Kovalenkov; Sanjeev Gumber; Jessica Y Huang; Raphael Gottardo; William Fulp; Alicia Sato; Sheetal Sawant; Sherry Stanfield-Oakley; Nicole Yates; Celia LaBranche; S Munir Alam; Georgia Tomaras; Guido Ferrari; David Montefiori; Jens Wrammert; Francois Villinger; Mark Tomai; John Vasilakos; Christopher B Fox; Steven G Reed; Barton F Haynes; Shane Crotty; Rafi Ahmed; Bali Pulendran
Journal:  Sci Immunol       Date:  2020-06-19

5.  Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization.

Authors:  Qifeng Han; Todd Bradley; Wilton B Williams; Derek W Cain; David C Montefiori; Kevin O Saunders; Robert J Parks; Regina W Edwards; Guido Ferrari; Olaf Mueller; Xiaoying Shen; Kevin J Wiehe; Steven Reed; Christopher B Fox; Wes Rountree; Nathan A Vandergrift; Yunfei Wang; Laura L Sutherland; Sampa Santra; M Anthony Moody; Sallie R Permar; Georgia D Tomaras; Mark G Lewis; Koen K A Van Rompay; Barton F Haynes
Journal:  Cell Rep       Date:  2020-02-04       Impact factor: 9.423

6.  AS03 stresses out macrophages: Commentary on 'Activation of the endoplasmic reticulum stress sensor IRE1α by the vaccine adjuvant AS03 contributes to its immunostimulatory properties'.

Authors:  Mark T Orr; Christopher B Fox
Journal:  NPJ Vaccines       Date:  2018-06-28       Impact factor: 7.344

Review 7.  Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity.

Authors:  Erica Stewart; James A Triccas; Nikolai Petrovsky
Journal:  Microorganisms       Date:  2019-08-12

Review 8.  Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.

Authors:  Adam N Pelletier; Rafick P Sekaly; Jeffrey A Tomalka
Journal:  Curr Opin Virol       Date:  2021-12-11       Impact factor: 7.090

Review 9.  "World in motion" - emulsion adjuvants rising to meet the pandemic challenges.

Authors:  Derek T O'Hagan; Robbert van der Most; Rushit N Lodaya; Margherita Coccia; Giuseppe Lofano
Journal:  NPJ Vaccines       Date:  2021-12-21       Impact factor: 7.344

10.  NLRP3 Inflammasome Participates in Host Response to Neospora caninum Infection.

Authors:  Xiaocen Wang; Pengtao Gong; Xu Zhang; Shan Li; Xiangyun Lu; Chunyan Zhao; Qile Yu; Zhengkai Wei; Yongjun Yang; Qun Liu; Zhengtao Yang; Jianhua Li; Xichen Zhang
Journal:  Front Immunol       Date:  2018-07-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.